Radiotherapy for 65 patients with advanced unresectable hepatocellular carcinoma

Table 2 Baseline characteristics of the 65 patients, according to treatment response

	Pts without OTR (n = 28)	Pts with OTR (n = 37)	P value
Age (yr)	61 ± 10	58 ± 8	0.271
Gender (M:F)	22:6	34:3	0.124
Hepatitis B	21 (75%)	28 (75.7%)	0.950
Hepatitis C	2 (7.1%)	1 (2.7%)	0.573
Alcohol abuse	5 (17.9%)	8 (21.6%)	0.707
WBC (/mm3)	5450 ± 1671	6079 ± 2229	0.216
Hemoglobin (g/dL)	11.4 ± 2.2	12.0 ± 1.8	0.207
Platelet (× 103/mm3)	160 ± 73	154 ± 608	0.733
AST (IU/L)	111 ± 93	71 ± 53	0.032
ALT (IU/L)	62 ± 51	69 ± 90	0.686
ALP (IU/L)	175 ± 89	134 ± 67	0.038
Bilirubin (mg/dL)	1.47 ± 1.27	0.91 ± 0.49	0.035
Albumin (g/dL)	3.3 ± 0.4	3.5 ± 0.5	0.103
Prothrombin time, INR	1.16 ± 0.22	1.15 ± 0.14	0.796
Creatinine (mg/dL)	1.17 ± 1.31	0.92 ± 0.25	0.329
Liver cirrhosis	21 (75%)	29 (78.4%)	0.749
Child-Pugh grade A	14 (50%)	31 (83.8%)	0.003
Alpha-fetoprotein (ng/dL)	31 474 ± 98 160	6844 ± 15 814	0.199
≥ 400 ng/dL	15 (53.6%)	22 (59.5%)	0.635
Tumor size (mm)	118 ± 37	99 ± 52	0.112
≥ 10 cm	18 (64.3%)	14 (37.8%)	0.035
Multiple tumor	24 (85.7%)	30 (81.1%)	0.622
Massive type	18 (64.3%)	20 (54.1%)	0.407
Main portal vein thrombosis	10 (35.7%)	10 (27%)	0.452
Tumor stage IV	23 (82.1%)	30 (81.1%)	0.913

OTR: Objective treatment response; WBC: White blood cell; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; INR: International normalized ratio; Tumor stage: According to the TNM staging system of Liver Cancer Study Group of Japan.